文献速递技术与安全儿科影像胸部PETCTMR

18F-FDG PET/CT评估朗格汉斯细胞组织细胞增生症临床试验入组资格优于常规解剖影像

Superiority of 18F-FDG PET/CT over conventional anatomical imaging in assessing clinical trial eligibility in Langerhans cell histiocytosis.
PubMed 文献 · Eur J Radiol · 2026-06-12

结果显示18F-FDG PET/CT检出534个病灶中的527个(98.7%),高于CT/MRI的499个(93.4%)。mPERCIST标准在病灶水平和患者水平均显著提高可测量性,较RECIST 1.1和PERCIST 1.0更适合临床试验设计与疗效评估。

要点

  • 18F-FDG PET/CT对LCH病灶检出率更高,并改变了15例患者的疾病分类
  • mPERCIST标准使病灶可测量率达97.8%,患者可评估率达96.6%,优于RECIST和PERCIST
  • PET/CT在识别适合临床试验入组的可测量病灶方面优于单独CT或MRI

核心结论

  • 18F-FDG PET/CT在识别朗格汉斯细胞组织细胞增生症可测量病灶方面优于常规解剖影像(CT/MRI)。
  • mPERCIST标准在病灶水平和患者水平均显著提高可测量性和可评估性,较RECIST 1.1和PERCIST 1.0更适合LCH临床试验设计和疗效评估。

研究设计与样本

  • 比较18F-FDG PET/CT与CT/MRI对受累病灶的检出率,并依据RECIST 1.1、PERCIST 1.0和mPERCIST标准评估可测量病灶。
  • 原文未报告研究中心数量、具体设备型号、扫描序列或参考标准细节。

关键影像表现/征象

  • 18F-FDG PET/CT共检出527个(98.7%)病灶,CT/MRI检出499个(93.4%)病灶,全部影像手段共识别534个病灶。
  • 与CT/MRI相比,18F-FDG PET/CT显著改变了15例患者的疾病分类。

诊断标准与关键数值

  • 在417个可测量病灶中,231个(55.4%)符合RECIST 1.1可测量标准,195个(46.8%)符合PERCIST 1.0标准,408个(97.8%)符合mPERCIST标准。
  • 患者水平上,116例(78.4%)经RECIST 1.1具有可测量病灶,101例(68.2%)经PERCIST 1.0具有可测量病灶,143例(96.6%)经mPERCIST具有可测量病灶。

临床应用与阅片要点

  • LCH患者行临床试验入组评估时,18F-FDG PET/CT比单独CT或MRI能识别更多可测量病灶,建议优先采用。
  • 采用mPERCIST标准可显著提高LCH病灶可测量率和患者可评估率,适合用于临床试验设计和治疗反应评估。

局限性

  • 原文未明确报告研究局限性,研究为回顾性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: We aimed to compare the performance of 18F-FDG PET/CT versus anatomic imaging (CT or MRI) for assessing clinical trial eligibility.

METHODS: This retrospective study enrolled pathologically confirmed LCH patients. A comparative analysis was conducted to assess the detection rates of involved lesions by 18F-FDG PET/CT versus CT/MRI. Furthermore, for enrollment in clinical trials, the study demonstrated the efficacy of these imaging modalities in identifying measurable disease at both lesion-based and patient-based levels, as defined by RECIST 1.1, PERCIST 1.0, and mPERCIST criteria.

RESULTS: One hundred forty-eight patients are included, composing of 84 adults and 64 pediatric patients. A total of 534 disease sites were identified among all imaging modalities, 527 (98.7 %) by 18F-FDG PET/CT, 499 (93.4 %) by CT/MRI. In comparison to CT/MRI, 18F-FDG PET/CT significantly altered disease classification in 15 patients. Among the 417 measurable lesions, 231 (55.4 %) met the measurability criteria of RECIST 1.1, 195 (46.8 %) met those of PERCIST 1.0, and 408 (97.8 %) met those of mPERCIST. At the patient level, 116 patients (78.4 %) had measurable disease sites by RECIST 1.1, 101 (68.2 %) by PERCIST 1.0, and 143 (96.6 %) by mPERCIST.

CONCLUSIONS: Compared with conventional anatomical imaging, 18F-FDG PET/CT demonstrates superior capability in identifying measurable disease sites in LCH. The mPERCIST criteria significantly improve both lesion measurability and evaluability relative to standard RECIST and PERCIST criteria, thereby offering enhanced utility for clinical trial design and therapeutic response assessment in LCH.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Guo, Sun, Zhou, et al. Superiority of 18F-FDG PET/CT over conventional anatomical imaging in assessing clinical trial eligibility in Langerhans cell histiocytosis. Eur J Radiol. 2026. PMID: 42314617. doi:10.1016/j.ejrad.2026.113009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。